艾昆纬-利用患者组织的力量：以PO驱动的超罕见病药物开发为例（英）-2024-16页_2mb

Analysis Summary

This document discusses the collaboration between pharmaceutical companies and patient organizations (POs) in the development of treatments for ultra-rare diseases, using the case of Alkaptonuria (AKU) and its treatment with nitisinone as an example.

Key points include:

• The significant challenges in rare disease research and development, which face hurdles like low patient numbers, difficulties in recruitment, and underpowered trials.
• POs play a vital role in facilitating clinical trials through their networks for patient identification, recruitment, retention, and support, overcoming practical barriers like travel costs and reimbursement.
• The success of the AKU trial was attributed to a robust trial design, collaboration with regulators, management support, persistent patient focus, and commitment from all partners, including pharma and academia.
• The case highlights that POs can drive the development process, bringing patient perspectives while primarily needing additional funding and capacity support. Pharma companies are encouraged to seek respectful collaborations and sponsor patient organizations to overcome these challenges.
• The document emphasizes the importance of joint efforts to create sustainable models for developing treatments for ultra-rare diseases, with POs acting as advocates and pharma providing clinical expertise and resources.

Case Study: Development of Nitisinone for AKU

The formation of a multi-stakeholder consortium (including POs, researchers, regulatory bodies, and the pharma company Sobi) was crucial to successfully conduct clinical trials for nitisinone in AKU. This involved detailed trial planning and execution, tailored to capture the disease's progression effectively using specific endpoints (HGA levels and AKUSSI). Patient engagement proved essential throughout, with high retention achieved by providing support and removing practical obstacles.

Lessons Learned and Recommendations

Successful PO-pharma collaboration requires:

• Sponsors from senior leadership.
• Respectful relationships and understanding of POs' resource limitations and primary goals (advocacy).
• Re-thinking commercial models to allow viable treatments for conditions with low financial returns.
• Addressing funding uncertainties through independent third parties to prevent conflicts of interest.
• Patient POs adopting an entrepreneurial mindset to foster collaborative success.
• Involving POs early in R&D processes for patient-centered outcomes.